Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.4Last Year’s EPS
-1.82Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: 7.21%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant revenue growth, successful product launches, and positive R&D progress. While there are potential challenges related to inventory management and competitive pressures, the overall sentiment remains optimistic due to the company's robust cash position and strategic planning.Company Guidance
In the first quarter of 2025, Incyte Corporation reported a robust financial performance with total revenues increasing by 20% year-over-year to $1.05 billion, driven by a 26% growth in product revenues. The company's cash position at the end of the quarter reached $2.4 billion. Jakafi's net product revenue grew 24% year-over-year to $709 million, with a 10% increase in total patients, prompting an upward revision of its full-year net product revenue guidance to $2.95-$3 billion. Opselura's net product revenue rose 38% to $119 million, supported by strong growth in the U.S. and European markets. The successful launch of Niktibo contributed $14 million in net product sales, highlighting significant early demand. The company is on track for a pivotal year with plans for three additional product launches and multiple pivotal trial readouts. Additionally, Incyte's strategic dual sourcing initiative is expected to minimize the impact of potential tariffs on pharmaceuticals.Strong Financial Performance
Q1 2025 saw a 26% growth in product revenue and a 20% increase in total revenues year over year, reaching $1.05 billion.
Successful Product Launches
Nikkynvo and Nick Timbo launched successfully, contributing $14 million in net product revenues in Q1 2025.
Jakafi Revenue Growth
Jakafi net product revenue grew 24% year over year to $709 million, with total patients increasing by 10%.
Opselura Growth
Opselura's Q1 net product revenue was $119 million, up 38% from the same quarter last year, driven by growth in the US and European markets.
Positive R&D Progress
Significant progress with positive data readouts in pivotal studies for HS and proof of concept in CSU.
Strong Cash Position
The company's cash position at the end of Q1 2025 was $2.4 billion.
---
INCY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
INCY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2025 | $59.52 | $60.43 | +1.53% |
Feb 10, 2025 | $74.13 | $68.30 | -7.86% |
Oct 29, 2024 | $65.69 | $73.60 | +12.04% |
Jul 30, 2024 | $68.59 | $67.79 | -1.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Incyte Corp (INCY) report earnings?
Incyte Corp (INCY) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Incyte Corp (INCY) earnings time?
Incyte Corp (INCY) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INCY EPS forecast?
INCY EPS forecast for the fiscal quarter 2025 (Q2) is 1.4.
---